Actuate Therapeutics, Inc./$ACTU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Actuate Therapeutics, Inc.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Ticker
$ACTU
Sector
Primary listing
Employees
12
Headquarters
Website
ACTU Metrics
BasicAdvanced
$29m
-
-$0.98
-
-
Price and volume
Market cap
$29m
52-week high
$9.22
52-week low
$1.16
Average daily volume
199k
Financial strength
Current ratio
1.804
Quick ratio
1.723
Interest coverage (TTM)
-1,078.36%
Profitability
Management effectiveness
Return on assets (TTM)
-203.78%
Return on equity (TTM)
3,304.83%
Valuation
Price to book
7.58
Price to tangible book (TTM)
7.58
Price to free cash flow (TTM)
-1.36
Free cash flow yield (TTM)
-73.54%
Free cash flow per share (TTM)
-0.89
Growth
Earnings per share change (TTM)
-50.31%
ACTU News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.